UBS Group
TTRX

UBS Group’s Turn Therapeutics TTRX Stock Holding History

UBS Group’s Portfolio TTRX Stock Details TTRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.28K Buy
+400
New +$1.56K ﹤0.01% 9562

Other funds holding TTRX

DI
DDFG Inc Thousand Oaks, California $464M AUM 16.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
WSC
Wellington Shields & Co New York $392M AUM 30.65% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
TS
Tamar Securities Woodland Hills, California $934M AUM 26.74% 1-Year Est. Return
BBHC
Brown Brothers Harriman & Co New York $18.6B AUM 15.81% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
RW
RVW Wealth Los Angeles, California $1.52B AUM 23.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

UBS Group's TTRX Position: Q1 2026 in Review

UBS Group opened a new position in Turn Therapeutics (TTRX) in Q1 2026: 400 shares worth $1.28K. The stake represents ﹤0.01% of the portfolio and ranks #9562 among its holdings.

20 funds tracked by Wall St. Rank hold TTRX as of Q1 2026.

  • UBS Group held 400 shares of Turn Therapeutics worth $1.28K as of Q1 2026.
  • Turn Therapeutics was a new UBS Group position in Q1 2026.
  • Turn Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #9562 holding.
  • 20 funds tracked by Wall St. Rank held Turn Therapeutics as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.